GE HealthCare (GEHC)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$68.86-1.23%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · GEHC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -19.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 5.1% |
Growth built into the price is above our model estimate.
The price assumes 25.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
GEHC — CEO transition
Dated 2026-08-18
CFO — William K. Grogan: The company appointed an external candidate as permanent CFO to replace an interim officer, which is a standard executive hiring event rather than a departure.
Why it matters: This will show if GE HealthCare can meet its growth targets. Falling below this mark may signal deeper issues.
Worry ifQ2 2026 revenue growth reported below 3.0%.
Less concerning ifQ2 2026 revenue growth reported above 3.0%.
Why it matters: The EBIT margin is important for making money. If it drops below 15.4%, it shows cost and inflation problems.
Worry ifAdjusted EBIT margin was below 15.4%.
Less concerning ifAdjusted EBIT margin was at or above 15.4%.
Why it matters: Changes in leadership can change financial plans. Smooth transitions are key for stability.
Watch forQ3 results show better financial numbers after the CFO change.
Also watch forQ3 results show a decline in financial metrics or guidance.
Why it matters: A smooth change is key for keeping investor trust and financial health.
Watch forThe new CFO uses good strategies. They do not change the financial guidance.
Also watch forNew CFO gives updated financial guidance that is not as good.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$109 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $338 loss on $10,000 · 3.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,247 loss on $10,000 · 32.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A lower EPS may show profit problems. This could lower investor confidence.
Worry ifAdjusted EPS reported below $0.85 in Q2 2026.
Less concerning ifAdjusted EPS reported at or above $0.85 in Q2 2026.
Why it matters: This acquisition aims to enhance GE HealthCare's cloud capabilities. Success could drive future growth.
Supportive ifIntelerad brought in more money in Q2 2026 results.
Worry ifIntelerad did not bring in much money in Q2 2026 results.
Why it matters: A stable CFO can help investor confidence and strategy.
Supportive ifA new CFO has been appointed.
Worry ifContinued interim status for the CFO beyond August 2026.
Why it matters: This could show problems in cash flow, affecting future investments.
Worry ifFree cash flow reported below $400 million.
Less concerning ifFree cash flow reported at $400 million or higher.
Why it matters: A decline shows ongoing problems with costs and making money.
Worry ifOperating income decreases from $515M in Q1 2026 to below $500M in Q2 2026.
Less concerning ifOperating income increases to above $515M in Q2 2026.
Why it matters: Hitting this goal shows strong market demand and good growth strategy execution.
Supportive ifOrganic revenue growth reported above 4% in Q3 or Q4 2026.
Worry ifOrganic revenue growth falls below 3% in the same period.
Why it matters: This shows problems with cash flow. It affects financial health.
Worry ifCash flow from operations reported below $250 million in Q2 2026.
Less concerning ifCash flow from operations reported above $290 million in Q2 2026.
Why it matters: A growing backlog shows strong demand. It also means more money for GE HealthCare in the future.
Supportive ifThe backlog was over $22 billion in Q2 2026.
Worry ifBacklog reported below $21.8 billion in Q2 2026.
Why it matters: Cash flow is vital for funding operations and growth. A decline below $150 million would raise concerns about financial health.
Worry ifCash flow from operations was below $150 million.
Less concerning ifCash flow from operations reported at or above $150 million.
Why it matters: William Grogan's leadership may change financial plans and growth. His success at Xylem shows he can improve profits and create new ideas.
Supportive ifLook for good financial results or plans announced within six months of September 14, 2026.
Worry ifBig problems in operations or finances show weak leadership or plans after the change.
Why it matters: This would signal a failure to meet the company's growth target and could raise concerns about market demand.
Worry ifQ3 organic revenue growth is below 3.0%.
Less concerning ifQ3 organic revenue growth is above 4.0%.
Why it matters: Missing this target may show problems in operations and hurt future investments.
Worry ifFree cash flow reported at or above $1.6 billion for 2026.
Less concerning ifFree cash flow reported below $1.4 billion for 2026.